Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134310 | 0.92 | GAA (0.45) | KDM4EALDH1A1ADORA1ADORA2AMAPT | |
| SCHEMBL6134129 | 0.90 | ADORA2A (0.48) | KDM4EALDH1A1ADORA1ADORA2AMAPT | |
| SCHEMBL6134147 | 0.89 | KDM4E (0.48) | KDM4EALDH1A1ADORA1ADORA2AADORA3 | |
| SCHEMBL6135802 | 0.89 | HTT (0.48) | KDM4EALDH1A1MAPTLMNATDP1 | |
| SCHEMBL6133600 | 0.88 | GRM5 (0.43) | ADORA1ADORA2AADORA3 | |
| SCHEMBL6134405 | 0.86 | KDM4E (0.40) | KDM4EALDH1A1ADORA1ADORA2AMAPT | |
| SCHEMBL6133862 | 0.85 | LMNA (0.45) | KDM4EALDH1A1ADORA3LMNATMIGD3 | |
| SCHEMBL6135302 | 0.84 | ALDH1A1 (0.37) | KDM4EALDH1A1ADORA1ADORA2AMAPT | |
| SCHEMBL6133749 | 0.84 | TP53 (0.44) | KDM4EALDH1A1ADORA1ADORA3LMNA | |
| SCHEMBL6134592 | 0.83 | ADORA1 (0.47) | ALDH1A1ADORA1ADORA2AMAPTADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | KDM4E 3364/4885ALDH1A1 801/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.